Skip to main content
SpringerLink
Log in

Risiko von Zweitmalignomen nach platinbasierter Chemotherapie von Hodentumoren

Risk of second malignancies after platinum-based chemotherapy of testicular cancer

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Thomas G, Sturgeon J, Alison R, Jewett M, Goldberg S, Sugar L et al (1989) A study of post-orchiectomy surveillance in stage I testicular seminoma. J Urol 142(2):313–316

    Article  CAS  PubMed  Google Scholar 

  2. Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R et al (2011) Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 29(8):957–962

    Article  CAS  PubMed  Google Scholar 

  3. Tandstad T, Ståhl O, Dahl O, Haugnes H, Håkansson U, Karlsdottir Å et al (2016) Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol 27(7):1299–1304

    Article  CAS  PubMed  Google Scholar 

  4. Tandstad T, Smaaland R, Solberg A, Bremnes RM, Langberg CW, Laurell A et al (2011) Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol 29(6):719–725

    Article  PubMed  Google Scholar 

  5. van de Wetering RA, Sleijfer S, Feldman DR, Funt SA, Bosl GJ, de Wit R (2018) Controversies in the management of clinical stage I seminoma: carboplatin a decade in-time to start backing out. J Clin Oncol 36(9):837

    Article  PubMed  Google Scholar 

  6. Mortensen MS, Bandak M, Kier MG, Lauritsen J, Agerbæk M, Holm NV et al (2017) Surveillance versus adjuvant radiotherapy for patients with high-risk stage I seminoma. Cancer 123(7):1212–1218

    Article  PubMed  Google Scholar 

  7. Aparicio J, Germà JR, Garcia del Muro X, Maroto P, Arranz JA, Sáenz A et al (2005) Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 23(34):8717–8723

    Article  PubMed  Google Scholar 

  8. Aparicio J, Maroto P, del Muro XG, Guma J, Sánchez-Munoz A, Margelí M et al (2011) Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol 29(35):4677–4681

    Article  PubMed  Google Scholar 

  9. Steiner H, Scheiber K, Berger AP, Rein P, Hobisch A, Aufderklamm J et al (2011) Retrospective multicentre study of carboplatin monotherapy for clinical stage I seminoma. BJU Int 107(7):1074–1079

    Article  CAS  PubMed  Google Scholar 

  10. Groot HJ, Lubberts S, de Wit R, Witjes JA, Kerst JM, de Jong IJ et al (2018) Risk of solid cancer after treatment of testicular germ cell cancer in the platinum era. J Clin Oncol 77:4174

    Google Scholar 

  11. Horwich A, Fossa SD, Huddart R, Dearnaley DP, Stenning S, Aresu M et al (2013) Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer 110:256

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsklinik für Radioonkologie, Eberhard Karls Universität, Tübingen, Deutschland

    David Utz &  Arndt-Christian Müller

Authors
  1. David Utz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arndt-Christian Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Utz.

Ethics declarations

Interessenkonflikt

D. Utz gibt an, dass kein Interessenkonflikt besteht. A.-C. Müller ist an der Erstellung der deutschen S3-Leitlinie der AWMF und der Deutschen Krebsgesellschaft als stellvertretender Mandatsträger der ARO beteiligt.

Additional information

Originalpublikation

Groot HJ, Lubberts S, de Wit R et al (2018) Risk of solid cancer after treatment of testicular germ cell cancer in the platinum era. J Clin Oncol 36(24):2504–2513

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Utz, D., Müller, AC. Risiko von Zweitmalignomen nach platinbasierter Chemotherapie von Hodentumoren. Strahlenther Onkol 195, 190–191 (2019). https://doi.org/10.1007/s00066-018-1410-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-018-1410-3

Search

Navigation